171 related articles for article (PubMed ID: 20584585)
1. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.
Koukourakis MI; Giatromanolaki A; Tsoutsou P; Lyratzopoulos N; Pitiakoudis M; Kouklakis G; Chloropoulou PA; Manolas K; Sivridis E
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):492-8. PubMed ID: 20584585
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
Czito BG; Bendell JC; Willett CG; Morse MA; Blobe GC; Tyler DS; Thomas J; Ludwig KA; Mantyh CR; Ashton J; Yu D; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):472-8. PubMed ID: 17498568
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study.
Koukourakis MI; Simopoulos C; Pitiakoudis M; Lyratzopoulos N; Romanidis K; Giatromanolaki A; Polychronidis A; Kouklakis G; Sivridis E; Minopoulos G; Manolas K
Anticancer Res; 2008; 28(5B):3035-40. PubMed ID: 19031952
[TBL] [Abstract][Full Text] [Related]
4. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial.
Resch G; De Vries A; Öfner D; Eisterer W; Rabl H; Jagoditsch M; Gnant M; Thaler J;
Radiother Oncol; 2012 Jan; 102(1):10-3. PubMed ID: 21741716
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Horisberger K; Treschl A; Mai S; Barreto-Miranda M; Kienle P; Ströbel P; Erben P; Woernle C; Dinter D; Kähler G; Hochhaus A; Post S; Willeke F; Wenz F; Hofheinz RD;
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1487-93. PubMed ID: 19131187
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.
Velenik V; Ocvirk J; Music M; Bracko M; Anderluh F; Oblak I; Edhemovic I; Brecelj E; Kropivnik M; Omejc M
Radiat Oncol; 2011 Aug; 6():105. PubMed ID: 21880132
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.
Crane CH; Eng C; Feig BW; Das P; Skibber JM; Chang GJ; Wolff RA; Krishnan S; Hamilton S; Janjan NA; Maru DM; Ellis LM; Rodriguez-Bigas MA
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):824-30. PubMed ID: 19464823
[TBL] [Abstract][Full Text] [Related]
8. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
Das P; Eng C; Rodriguez-Bigas MA; Chang GJ; Skibber JM; You YN; Maru DM; Munsell MF; Clemons MV; Kopetz SE; Garrett CR; Shureiqi I; Delclos ME; Krishnan S; Crane CH
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):301-5. PubMed ID: 24315563
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J
Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204.
Landry JC; Feng Y; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Prabhu RS; Benson AB
Cancer; 2013 Apr; 119(8):1521-7. PubMed ID: 23288663
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer.
Gasparini G; Torino F; Ueno T; Cascinu S; Troiani T; Ballestrero A; Berardi R; Shishido J; Yoshizawa A; Mori Y; Nagayama S; Morosini P; Toi M
Angiogenesis; 2012 Mar; 15(1):141-50. PubMed ID: 22212406
[TBL] [Abstract][Full Text] [Related]
12. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Nogué M; Salud A; Vicente P; Arriví A; Roca JM; Losa F; Ponce J; Safont MJ; Guasch I; Moreno I; Ruiz A; Pericay C;
Oncologist; 2011; 16(5):614-20. PubMed ID: 21467148
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J
Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.
Rödel C; Arnold D; Hipp M; Liersch T; Dellas K; Iesalnieks I; Hermann RM; Lordick F; Hinke A; Hohenberger W; Sauer R
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1081-6. PubMed ID: 17881150
[TBL] [Abstract][Full Text] [Related]
15. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Ofner D; Devries AF; Schaberl-Moser R; Greil R; Rabl H; Tschmelitsch J; Zitt M; Kapp KS; Fastner G; Keil F; Eisterer W; Jäger R; Offner F; Gnant M; Thaler J;
Strahlenther Onkol; 2011 Feb; 187(2):100-7. PubMed ID: 21267531
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R
Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study.
Hong YS; Kim DY; Lim SB; Choi HS; Jeong SY; Jeong JY; Sohn DK; Kim DH; Chang HJ; Park JG; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1171-8. PubMed ID: 20605355
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
Dipetrillo T; Pricolo V; Lagares-Garcia J; Vrees M; Klipfel A; Cataldo T; Sikov W; McNulty B; Shipley J; Anderson E; Khurshid H; Oconnor B; Oldenburg NB; Radie-Keane K; Husain S; Safran H
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):124-9. PubMed ID: 20947267
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
Machiels JP; Sempoux C; Scalliet P; Coche JC; Humblet Y; Van Cutsem E; Kerger J; Canon JL; Peeters M; Aydin S; Laurent S; Kartheuser A; Coster B; Roels S; Daisne JF; Honhon B; Duck L; Kirkove C; Bonny MA; Haustermans K
Ann Oncol; 2007 Apr; 18(4):738-44. PubMed ID: 17208931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
